Previous 10 | Next 10 |
CASI Pharmaceuticals (CASI) trades 12.7% down premarket after pricing its earlier announced underwritten public offering of 15.8M shares at $2.05/share; underwriters granted 30-day option to purchase up to an additional 2.38M shares.Offering is expected to close on or abou...
CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock PR Newswire ROCKVILLE, Md. and BEIJING , March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing...
Benitec Biopharma (BNTC) -21%.Second Sight Medical Products (EYES) -21% on $28M capital raise.Takung Art (TKAT) -17%.Evolve Transition Infrastructure (SNMP) -15%.GameStop (GME) -14% on Q4 earnings release.CASI Pharmaceuticals (CASI) -12% after proposes stock offering....
CASI Pharmaceuticals (CASI) trades 7% down after hours on commencing an underwritten public offering to issue and sell shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms have not yet been disclosed.Net proceeds to be used f...
CASI Pharmaceuticals To Host Business Update Call March 12, 2021 PR Newswire ROCKVILLE, Md. and BEIJING , March 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing...
CASI Pharmaceuticals (CASI) and Cleave Therapeutics have agreed to jointly develop and commercialize CB-5339, a novel VCP/p97 inhibitor, in mainland China, Taiwan, Hong Kong, and Macau.CASI is responsible for development and commercialization in China and related markets and will pa...
Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region ~ CASI's pipeline expanded to include first-in-class VCP/p97 inhibitor in Phase 1 for hematological malignancies and solid tumors ~~ Cleave to receive $5.5 ...
CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates ~ Expects to Report EVOMELA® (melphalan for injection) Fourth Quarter 2020 Unaudited Revenue of Approximately $4.8 Million and Full-Year 2020 Unaudited Revenu...
CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients -Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore act...
BioInvent International (BOVNF) and partner CASI Pharmaceuticals (CASI) announce positive interim results from the Phase I/IIa trial of novel anti-FcγRIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refr...
News, Short Squeeze, Breakout and More Instantly...
CASI Pharmaceuticals Inc. Company Name:
CASI Stock Symbol:
NASDAQ Market:
CASI Pharmaceuticals Inc. Website:
2024-07-17 13:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP PR Newswire BEIJING , July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing in...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...